# EDGAR Filing Document

**Accession Number:** 0001937737
**File Stem:** 0001213900-26-020760
**Filing Date:** 2026-2
**Character Count:** 8230
**Document Hash:** 620a6427638b8cdd737c417d5b66426b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-020760.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001213900-26-020760

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260226

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Moolec Science SA
- **CENTRAL INDEX KEY:** 0001937737
- **STANDARD INDUSTRIAL CLASSIFICATION:** TEXTILE MILL PRODUCTS [2200]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41586
- **FILM NUMBER:** 26687638

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 89 NEXUS WAY, CAMANA BAY
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-9009
- **BUSINESS PHONE:** 352 26 49 65 65

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 89 NEXUS WAY, CAMANA BAY
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-9009

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of the** 

**Securities Exchange Act of 1934**

**For the month of February 2026**

**Commission File Number: 001-41586**

**MOOLEC SCIENCE SA**

(Exact name of Registrant as Specified in Its Charter)

**89 Nexus Way, Camana Bay**

**Grand Cayman KY1-9009**

**Cayman Islands**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**EXPLANATORY NOTE**

The information contained in this Form 6-K and any exhibits hereto shall be deemed to be incorporated by reference into the Company's registration statement on [Form S-8](http://www.sec.gov/Archives/edgar/data/1937737/000121390024080686/ea0214775-s8_moolec.htm) (Registration No. 333-282263).

**EXHIBIT INDEX**

The following exhibit is filed as part of this Form 6-K:

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [Press Release dated February 25, 2025, titled "Moolec Science SA Announces Changes to Board of Directors](ea027849001ex99-1_moolec.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Moolec Science SA | Moolec Science SA |
|  | (registrant) | (registrant) |
| Date: February 26, 2026 | By: | /s/ Alejandro Antalich |
|  | Name: | Alejandro Antalich |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Moolec Science SA Announces Changes to Board of Directors**

Moolec Science SA (NASDAQ: MLEC) (the "Company"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced changes to the composition of its Board of Directors.

**Appointment of Director**

Daniel Core has been appointed to the Company's Board of Directors, effective February 25, 2025. Mr. Core has also been appointed as a member of the Audit Committee and the Compensation Committee of the Board.

Daniel Core is a U.S.-based quality and operations professional with more than three decades of experience in industrial manufacturing environments. His background includes quality leadership roles across multinational and precision manufacturing organizations, with a focus on operational discipline, compliance, and process integrity.

Mr. Core has held quality assurance and quality leadership positions with organizations including Illinois Tool Works, MW Components, Aptix, and Stanley Black & Decker. His experience spans the implementation and oversight of established quality management systems and regulatory frameworks commonly applied in regulated manufacturing sectors. He has extensive experience supporting internal and external audit processes, strengthening quality systems, and contributing to continuous improvement initiatives focused on risk reduction, cost discipline, and operational efficiency. Mr. Core currently serves in a quality leadership role within the manufacturing sector in New England.

He brings a disciplined, systems-oriented perspective to Board discussions, informed by hands-on experience with quality governance, compliance environments, and operational risk management.

**Resignation of Directors**

Aimar Dimo and Gloria Montaron Estrada have each resigned from the Company's Board of Directors, effective February 25, 2025.

The Company sincerely thanks Mr. Dimo and Ms. Montaron Estrada for their dedicated service and valuable contributions to the Company and its shareholders during their tenure.

**About Moolec Science SA**

Moolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 52 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please visit www.moolecscience.com and ir.moolecscience.com.

**Forward Looking Statements**

This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Moolec Science's Contacts:

● Investor Relations inquiries: ir@moolecscience.com